Xiaohong Xie

Xiaohong Xie

Auto-generated profile, based on publicly available information

Xiaohong Xie

Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2017 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
WLwang jin lin
wang jin lin
JLJun Liu
Jun Liu
XXXiaohong Xie
Xiaohong Xie
PSPanxiao Shen
Panxiao Shen
JHJianxing He
Jianxing He
YZYunxiang Zeng
Yunxiang Zeng
Although pleural fluid lactate dehydrogenase (LDH) and adenosine deaminase (ADA) levels are often used to distinguish between tuberculous pleural effusion (TPE) and parapneumonic pleural effusion (PPE), this can be challenging as the LDH level may vary from normal to severely increased in PPE and a significantly elevated ADA is frequently measured in both conditions. In this study, we evaluated use of the pleural fluid LDH/ADA ratio as a new parameter to discriminate TPE from PPE. A retrospective study was conducted in patients with pathologically-confirmed TPE (n = 72) and PPE (n = 47) to compare pleural fluid LDH and ADA levels and LDH/ADA ratios between the 2 groups. A receiver operating characteristic (ROC) curve was constructed for identifying TPE. The median pleural fluid LDH and ADA levels and LDH/ADA ratios in the TPE and PPE groups were: 364.5 U/L vs 4037 U/L (P < .001), 33.5 U/L vs 43.3 U/L (P = .249), and 10.88 vs 66.91 (P < .0001), respectively. An area under the ROC curve of 0.9663 was obtained using the LDH/ADA ratio as the indicator for TPE identification, and the sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were, respectively, 93.62%, 93.06%, 13.48, and 0.068 at a cut-off level of 16.20. The pleural fluid LDH/ADA ratio, which can be determined from routine biochemical analysis, is highly predictive of TPE at a cut-off level of 16.20. Measurement of this parameter may be helpful for clinicians in distinguishing between TPE and PPE.

1 May 2026 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
TLTao Luan
Tao Luan
KMKangjing Ma
Kangjing Ma
SWShuaiying Wang
Shuaiying Wang
QYQingqing Yang
Qingqing Yang
HMHongbin Ma
Hongbin Ma
CZChengzhi Zhou
Chengzhi Zhou
Background: Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced lung cancer, but immune checkpoint inhibitor-associated myocarditis (ICIM), particularly severe ICIM, remains a rare yet potentially fulminant and fatal immune-related adverse event (irAE). We aimed to develop and externally validate a clinically accessible risk-prediction model based on routine baseline cardiac assessments to enable early identification and risk stratification of patients at high risk of severe ICIM around ICI initiation. Methods: This multicenter retrospective study included a training set, an internal validation set, and an external validation set. Patients with early-stage lung cancer, no ICI exposure, incomplete baseline cardiac evaluation [electrocardiogram (ECG)/echocardiography], missing predictor data, or insufficient follow-up were excluded; pre-existing cardiovascular comorbidities were not exclusionary and were recorded as baseline characteristics. The primary endpoint was severe ICIM [Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade ≥3]. Candidate predictors [high-sensitivity troponin, B-type natriuretic peptide (BNP), ECG, and echocardiography] were obtained from baseline/routine assessments at ICI initiation, prior to any ICIM event. Model Discrimination was assessed using receiver operating characteristic curve/area under the curve (ROC/AUC) with calibration plots and decision curve analysis (DCA) evaluating calibration and clinical utility. Results: A total of 834 patients were enrolled, with an overall mean age of 60 years [standard deviation (SD) =14]; by cohort, mean ages were approximately 59 years (training set), 61 years (internal validation set), and 61 (external validation set) years. Males accounted for 79.5% of the total cohort, with a slightly higher proportion in the internal validation set (83.2%) compared to the training (75.5%) and external validation (81.4%) sets. The prevalence of smoking was 61.0% and comparable across cohorts; 52.3% had comorbidities. Adenocarcinoma was the most common subtype (39.8%), followed by squamous cell carcinoma (35.4%), with similar distributions across cohorts. Based on these cohorts, four readily available predictors (troponin, BNP, ECG, echocardiography) were retained to construct the severe ICIM model and nomogram. The AUCs were 0.926 [95% confidence interval (CI): 0.880–0.971] in the training set, 0.885 (95% CI: 0.742–1.000) in the internal validation set, and 0.949 (95% CI: 0.884–1.000) in the external validation set; calibration plots and DCA demonstrated favorable agreement between predicted and actual outcomes, as well as significant net benefit across clinically relevant thresholds. Conclusions: This four-predictor severe ICIM risk model and nomogram, developed from multicenter real-world data and externally validated, supports early risk stratification and monitoring strategies for advanced lung cancer patients receiving ICIs. Prospective studies are warranted to confirm its generalizability and optimize implementation.

12 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TLTao Luan
Tao Luan
XLXinqing Lin
Xinqing Lin
XXXiao Hong Xie
Xiao Hong Xie
SWShuaiying Wang
Shuaiying Wang
HLHeng Lu
Heng Lu
CZChengzhi Zhou
Chengzhi Zhou
Human Epidermal Growth Factor Receptor 2(HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. It is generally considered as a poor prognostic marker. Targeted therapies, such as small molecule tyrosine kinase inhibitors (TKIs), showed limited efficacy in HER2-mutant advanced Non-Small Cell Lung Cancer (NSCLC). In the 2023 NCCN guidelines for NSCLC, Antibody-Drug Conjugate(ADC) Trastuzumab emtansine (T-DM1) is recommended for the treatment of HER2-mutant Lung Cancer (LC). However, this medication is currently not approved in certain regions.So it is necessary to explore alternative treatment options for HER2-mutant NSCLC patients.In our study of a patient with HER2 exon 20ins Lung Adenocarcinoma who had previously failed multiple TKI treatments, we discovered that Sunvozertinib could stabilize the patient's condition, achieving a progression-free survival (PFS) of 87 days. This is a novel finding that may provide new treatment options for HER2 exon 20ins patients who have failed TKI therapy.

5 April 2026 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
LWLiqiang Wang
Liqiang Wang
CZChulan Zhan
Chulan Zhan
QHQiying Huang
Qiying Huang
HGHaonan Gao
Haonan Gao
TLTong Lin
Tong Lin
CZChengzhi Zhou
Chengzhi Zhou
Accurate prognostic assessment of primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) remains challenging. We analyzed clinicopathological data fro